T he Food and Drug Administration’s most recent steps toward modernizing the drug approval process have renewed some old questions about the FDA’s relationship with the industries it regulates. Several public advocacy groups affi liated with physicians and researchers have voiced their concern over the appointment of certain members to a newly formed agency board. The groups have warned that so...

In this issue of Bioengineering & Translational Medicine, we proudly feature Dr. Raghunath Mashelkar. He is the President of Global Research Alliance, world’s largest network of Research and Technology Organizations dedicated to creating global good through global knowledge partnerships. He is also the Chairperson of the National Innovation Foundation of India, which promotes grassroots innovat...

In this issue, we welcome 11 new members to our Editorial Advisory Board. The Board serves a vital function for the Journal. They are a board of reviewers who are particularly dedicated to the Journal; we rely on them heavily. We ask their advice and recommendation about whether to send out for full review submitted manuscripts that are outside our recognized scope. They act as guest editors wh...